^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

Excerpt:
A 6-gene WNT pathway signature showed significant association with progression-free survival (PFS) and overall survival (OS) for the biomarker high versus biomarker low groups (PFS: p = 0.029 and OS: p = 0.00045, respectively).
Secondary therapy:
paclitaxel
DOI:
10.1007/s10549-020-05817-w
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Abstract P3-07-57: Development of a 6-gene qPCR RUO-validated assay as a predictive biomarker for response of vantictumab (OMP-18R5; anti-frizzled) in HER2- breast cancer patients

Excerpt:
6-gene qPCR RUO-validated assay developed as a predictive biomarker for response of VAN in HER2-negative breast cancer patients;
DOI:
10.1158/1538-7445.SABCS15-P3-07-57